Galectin Therapeutics Inc
GALT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001133416
In the last 90 days, Galectin Therapeutics Inc insiders filed 0 open-market purchases and 3 sales; 98 institutions reported holding it in 13F filings for Q2 2026, worth $72.2M in total; no superinvestor holds it.
Holders of 5% or more of GALT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Galectin Therapeutics Inc, largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Galectin Therapeutics Inc on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
Schedule 13D and 13G filings on Galectin Therapeutics Inc, newest first.
No Schedule 13D or 13G filings on Galectin Therapeutics Inc are on file.
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Galectin Therapeutics Inc shares.
No Form 144 notices for Galectin Therapeutics Inc are on file.